Cerecor (CERC) Surges with Alkermes (ALKS) Following Positive Depression Trial Results
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Moody's Says Alkermes (ALKS) FORWARD-5 Data is Credit-Positive Development
October 21, 2016 2:31 PM EDTMoody's Investors Service commented that the positive clinical data of Alkermes' (Nasdaq: ALKS) experimental depression drug ALKS-5461 is credit positive. There is no effect on Alkermes' ratings including the Ba3 Corporate Family Rating, or the negative rating outlook.
... MoreAlkermes (ALKS) PT Raised to $70 at Leerink Partners
October 21, 2016 6:41 AM EDTLeerink Partners analyst Paul Matteis reiterated an Outperform rating and raised its price target on Alkermes (NASDAQ: ALKS) to $70.00 (from $57.00) after the company announced positive results from their third ph3 study for ALKS5461 in depression.
Matteis commented, "We were previously... More